# US 2013/0253201 A1 · Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253201 A1
- Document ID: US20130253201A1
- Status: Published application
- Kind: A1
- Application number: 13/897,087
- Filed: 2013-05-17
- Published: 2013-09-26
- Earliest claimed: 2006-04-03
- Assignees: Hoffmann-La Roche Inc.
- Inventors: Stephan Bachmann; Michelangelo Scalone; Patrick Schnider
- Web page: https://patentgrep.com/patent/US20130253201A1

## CPC

- C07C 51/36: by hydrogenation of carbon-to-carbon unsaturated bonds
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/60: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to a process for the preparation of cis substituted cyclic β-aryl or heteroaryl carboxylic acid derivatives in high diastereo- and enantioselectivity by enantioselective hydrogenation in accordance with the following scheme wherein X, Ar, n, and m are defined herein and corresponding salts thereof.

## Claims

### Claim 1

A process for the preparation of enantiomerically enriched cyclic β-arylcarboxylic acid derivatives of formula
wherein
X is —C(R)(R′)—, —N(R″)—, —O—, —S(O)O—, C(O)N(R″), —N(R″)C(O)— or —C(O)—;
R and R′ are each independently hydrogen, C1-7-alkyl, C1-7-alkyl substituted by halogen, C1-7-alkoxy, hydroxy or —(CH2)p—Ar;
R″ is hydrogen, C1-7-alkyl, C1-7-alkyl substituted by halogen, —S(O)o—C1-7-alkyl, —S(O)o—Ar, —S(O)o—NRR′, —(CH2)p—Ar, —C(O)—Ar, —C(O)—NRR′ or —C(O)O—C1-7-alkyl;
Ar is aryl1 or heteroaryl1;
n is 0, 1, 2 or 3;
m is 0, 1, 2 or 3;
o is 0, 1 or 2; and
p is 0, 1, or 2;
or a pharmaceutically acceptable salt thereof
comprising catalytic homogeneous enantioselective hydrogenation of a compound of formula (II)
in the presence of a catalyst comprising
Ru(Z)2D XVII
or
[Ru(Z)2-p(D)(L1)m](B)p XVIII
wherein Z represents halogen or the group A-COO,
A represents lower alkyl, aryl2, halogenated lower alkyl or halogenated aryl2,
D represents a chiral diphosphine ligand,
B represents a non-coordinating anion,
L1 represents a neutral ligand,
p represents the numbers 1 and 2,
the ligands can be the same or different, and
m represents the numbers 1, 2 or 3.

### Claim 2 (depends on 1)

The process of claim 1, wherein Z is CH3COO, CF3COO or a halogenide.

### Claim 3 (depends on 1)

The process of claim 1, wherein the chiral diphosphine ligand is selected from the group consisting of
and
wherein
R4 is lower-alkyl;
R5 is lower-alkyl;
R6 is independently aryl2, heteroaryl2, cycloalkyl or lower-alkyl;
R7 is N(lower-alkyl)2 or piperidinyl;
R8 is lower-alkyl, lower-alkoxy, hydroxy or lower-alkyl-C(O)O—;
R9 and R10 are each independently hydrogen, lower-alkyl, lower-alkoxy or di(lower-alkyl)amino; or
R8 and R9 which are attached to the same phenyl group, or R9 and R10 which are attached to the same phenyl group, or both R8, taken together, are —X—(CH2)n—Y—, wherein X is —O— or —C(O)O—, Y is —O— or —N(lower-alkyl)- and n is an integer from 1 to 6, or a CF2 group; or
R8 and R9, or R9 and R10, together with the carbon atoms to which they are attached, form a naphthyl, tetrahydronaphthyl or dibenzofuran ring;
R11 and R12 are each independently lower alkyl, cycloalkyl, phenyl, napthyl or heteroaryl, substituted with 0 to 7 substituents independently selected from the group consisting of lower-alkyl, lower-alkoxy, di(lower-alkyl)amino, morpholino, phenyl and tri(lower-alkyl)silyl.

### Claim 4 (depends on 3)

The process of claim 3, wherein D represents a chiral diphosphine ligand selected from the group consisting of formula (7), (9), (10) or (12).

### Claim 5 (depends on 4)

The process of claim 4, wherein the chiral diphosphine is selected from the group consisting of (R) and (S)-enantiomers of MeOBIPHEP, BIPHEMP, TMBTP, 2-Naphthyl)-MeOBIPHEP, (6-MeO-2-Naphthyl)-MeOBIPHEP, 2-(Thienyl)-MeOBIPHEP, 3,5-tBu-MeOBIPHEP, PHANEPHOS, BICP, TriMeOBIPHEP, (R,R,S,S)-Mandyphos, BnOBIPHEP, BenzoylBIPHEP, pTol-BIPHEMP, tButylCOOBIPHEP, iPrOBIPHEP, p-Phenyl-MeOBIPHEP, pAn-MeOBIPHEP, pTol-MeOBIPHEP, 3,5-Xyl-MeOBIPHEP, 3,5-Xyl-BIPHEMP, BINAP and 2-Furyl-MeOBIPHEP, 3,5-Xyl-4-MeO-MeOBIPHEP, 2-Furyl-MeOBIPHEP, and BITIANP.

### Claim 6 (depends on 5)

The process of claim 5, wherein the chiral diphosphine is (S)-(6-MeO-2-Naphthyl)-MeOBIPHEP, 3,5-Xyl-4-MeO-MeOBIPHEP, (S)-2-Furyl-MeOBIPHEP or BITIANP.

### Claim 7 (depends on 1)

The process of claim 1, wherein the catalyst is selected from the group consisting of (R) and (S) enantiomers of [Ru(CH3COO−)2(TMBTP)], [Ru(CF3COO−)2(TMBTP)], [Ru(CH3COO−)2(2-naphthyl)-MeOBIPHEP)], [Ru(CF3COO−)2(2-naphthyl)-MeOBIPHEP)], [Ru(CH3COO−)2(6-MeO-2-naphthyl)-MeOBIPHEP)] and [Ru(CF3COO−)2(6-MeO-2-naphthyl)-MeOBIPHEP)].

### Claim 8 (depends on 1)

The process of claim 1, wherein the catalytic hydrogenation is carried out at a pressure of 1 to 150 bar.

### Claim 9 (depends on 8)

The process of claim 8, wherein the catalytic hydrogenation is carried out at a pressure of 10 to 100 bar.

### Claim 10 (depends on 1)

The process of claim 1, wherein the catalytic hydrogenation is carried out at a temperature of 10 to 100° C.

### Claim 11 (depends on 10)

The process of claim 10, wherein the catalytic hydrogenation is carried out at a temperature of 20 to 80° C.

### Claim 12 (depends on 1)

The process claim 1, wherein the catalytic hydrogenation is carried out in the presence of a base.

### Claim 13 (depends on 12)

The process of claim 12, wherein the base is selected from the group consisting of NEt3, i-Pr2NEt, i-Pr2NH, C6H5CH2NH2, 1-phenyl-benzylamine, (R) or (S) ethylene diamine, tetramethylethylene diamine, NaOAc, NaOEt, NaOH and Bu4NX, wherein X is F, Cl, Br or I.

### Claim 14 (depends on 13)

The process of claim 13, wherein the base is NEt3 or i-Pr2Net.

### Claim 15 (depends on 1)

The process of claim 1, wherein the catalytic hydrogenation is carried out in a solvent.

### Claim 16 (depends on 15)

The process of claim 15, wherein the solvent is selected from the group consisting of an alcohol, hydrocarbon, chlorinated hydrocarbon, THF, water, and a mixture thereof.

### Claim 17 (depends on 16)

The process of claim 16, wherein the solvent is methanol or ethanol.

### Claim 18 (depends on 15)

The process of claim 15, wherein the concentration of solvents is 1-50 W %.

### Claim 19 (depends on 1)

The process of claim 1, wherein the ratio of substrate/catalyst (s/C) is 5:30000.

### Claim 20 (depends on 1)

The process of claim 1, wherein the compound of formula (I) is selected from the group consisting of
2-aryl/heteroaryl-cyclopentane carboxylic acids,
4-aryl/heteroaryl-2,5-dihydro-1H-pyrrolidine-3-carboxylic acids,
4-aryl/heteroaryl-tetrahydrofuran-3-carboxylic acids,
4-aryl/heteroaryl-tetrahydro-thiophene-3-carboxylic acids,
1,1-dioxo-4-aryl/heteroaryl-tetrahydro-1λ6-thiophene-3-carboxylic acids,
1-oxo-4-aryl/heteroaryl-tetrahydro-1λ4-thiophene-3-carboxylic acids,
2-aryl/heteroaryl-cyclohexane carboxylic acid,
4-aryl/heteroaryl-piperidine-3-carboxylic acids,
5-aryl/heteroaryl-piperidine-4-carboxylic acids, and
4-aryl/heteroaryl-tetrahydro-pyran-3-carboxylic acids or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

The process of claim 1, wherein the compound of formula (I) is selected from the group consisting of
5-aryl/heteroaryl-tetrahydro-pyran-4-carboxylic acids,
4-aryl/heteroaryl-tetrahydro-thiopyran-3-carboxylic acids,
5-aryl/heteroaryl-tetrahydro-thiopyran-4-carboxylic acids,
1,1-dioxo-4-aryl/heteroaryl-hexahydro-1λ6-thiopyran-3-carboxylic acids,
1,1-dioxo-5-aryl/heteroaryl-hexahydro-1λ6-thiopyran-4-carboxylic acids,
1-oxo-4-aryl/heteroaryl-hexahydro-1λ4-thiopyran-3-carboxylic acids,
2-phenyl-cycloheptane carboxylic acid, and
2-phenyl-cyclooctane carboxylic acid or a pharmaceutically acceptable salt thereof.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

A process for the preparation of enantiomerically enriched cyclic β-arylcarboxylic acid derivatives of formula
wherein
X is —C(R)(R′)—, —N(R″)—, —O—, C(O)N(R″), —N(R″)C(O)— or —C(O)—;
R and R′ are each independently hydrogen, C1-7-alkyl, C1-7-alkyl substituted by halogen, C1-7-alkoxy, hydroxy or —(CH2)p—Ar;
R″ is hydrogen, C1-7-alkyl, C1-7alkyl substituted by halogen, —S(O)o—C1-7-alkyl, —S(O)o—Ar, —S(O)o—NRR′, —(CH2)p—Ar, —C(O)—Ar, —C(O)—NRR′ or
Ar is aryl1 or heteroaryl1;
n is 0, 1, 2 or 3;
m is 0, 1, 2 or 3;
o is 0, 1 or 2;
p is 0, 1, or 2;
or a pharmaceutically acceptable salt thereof
comprising catalytic homogeneous enantioselective hydrogenation of a compound of formula (II)
in the presence of a catalyst comprising
[Rh(chiral diphosphine)LX] or [Rh(chiral diphosphine)L]+A−
wherein X is Cl−, Br− or I−,
L is a neutral ligand, selected from the group consisting of ethylene, propylene, cyclooctene, 1,3-hexadiene, norbornadiene, 1,5-cyclooctadiene, benzene, hexamethylbenzene, 1,3,5-trimethylbenzene, p-cymene, tetrahydrofuran, dimethylformamide, acetonitrile, benzonitrile, acetone and methanol, A is an anion of an oxyacid or a complex acid selected from the group consisting of ClO4, PF6, BR4, wherein R is halogen or aryl, SbF6 and AsF6.

### Claim 27 (depends on 26)

The process of claim 26, wherein the chiral diphosphine ligand is selected from the group consisting of
and
wherein
R4 is lower-alkyl;
R5 is lower-alkyl;
R6 independently is aryl2, heteroaryl2, cycloalkyl or lower-alkyl;
R7 is N(lower-alkyl)2 or piperidinyl;
R8 is lower-alkyl, lower-alkoxy, hydroxy or lower-alkyl-C(O)O—;
R9 and R10 are each independently hydrogen, lower-alkyl, lower-alkoxy or di(lower-alkyl)amino; or
R8 and R9 which are attached to the same phenyl group, or R9 and R10 which are attached to the same phenyl group, or both R8, taken together, are —X—(CH2)n—Y—, wherein X is −O— or —C(O)O—, Y is —O— or —N(lower-alkyl)- and n is an integer from 1 to 6, or a CF2 group; or
R8 and R9, or R9 and R10, together with the carbon atoms to which they are attached, form a naphthyl, tetrahydronaphthyl or dibenzofuran ring;
R11 and R12 are each independently lower alkyl, cycloalkyl, phenyl, napthyl or heteroaryl, substituted with 0 to 7 substituents independently selected from the group consisting of lower-alkyl, lower-alkoxy, di(lower-alkyl)amino, morpholino, phenyl and tri(lower-alkyl)silyl.

### Claim 28 (depends on 27)

The process of claim 27, wherein D represents a chiral diphosphine ligand selected from the group consisting of formula (7), (9), (10) or (12).

### Claim 29 (depends on 28)

The process of claim 28, wherein the chiral diphosphine is selected from the group consisting of (R) and (S)-enantiomers of MeOBIPHEP, BIPHEMP, TMBTP, 2-Naphthyl)-MeOBIPHEP, (6-MeO-2-Naphthyl)-MeOBIPHEP, 2-(Thienyl)-MeOBIPHEP, 3,5-tBu-MeOBIPHEP, PHANEPHOS, BICP, TriMeOBIPHEP, (R,R,S,S)-Mandyphos, BnOBIPHEP, BenzoylBIPHEP, pTol-BIPHEMP, tButylCOOBIPHEP, iPrOBIPHEP, p-Phenyl-MeOBIPHEP, pAn-MeOBIPHEP, pTol-MeOBIPHEP, 3,5-Xyl-MeOBIPHEP, 3,5-Xyl-BIPHEMP, BINAP and 2-Furyl-MeOBIPHEP, 3,5-Xyl-4-MeO-MeOBIPHEP, 2-Furyl-MeOBIPHEP, and BITIANP.

### Claim 30 (depends on 29)

The process of claim 29, wherein the chiral diphosphine is (S)-(6-MeO-2-Naphthyl)-MeOBIPHEP, 3,5-Xyl-4-MeO-MeOBIPHEP, (S)-2-Furyl-MeOBIPHEP or BITIANP.

### Claim 31 (depends on 26)

The process of claim 26, wherein the catalytic hydrogenation is carried out at a pressure of 1 to 150 bar.

### Claim 32 (depends on 31)

The process of claim 31, wherein the catalytic hydrogenation is carried out at a pressure of 10 to 100 bar.

### Claim 33 (depends on 26)

The process of claim 26, wherein the catalytic hydrogenation is carried out at a temperature of 10 to 100° C.

### Claim 34 (depends on 33)

The process of claim 33, wherein the catalytic hydrogenation is carried out at a temperature of 20 to 80° C.

### Claim 35 (depends on 26)

The process claim 26, wherein the catalytic hydrogenation is carried out in the presence of a base.

### Claim 36 (depends on 35)

The process of claim 35, wherein the base is selected from the group consisting of NEt3, i-Pr2NEt, i-Pr2NH, C6H5CH2NH2, 1-phenyl-benzylamine, (R) or (S) ethylene diamine, tetramethylethylene diamine, NaOAc, NaOEt, NaOH and Bu4NX, wherein X is F, Cl, Br or I.

### Claim 37 (depends on 36)

The process of claim 36, wherein the base is NEt3 or i-Pr2Net.

### Claim 38 (depends on 26)

The process of claim 26, wherein the catalytic hydrogenation is carried out in a solvent.

### Claim 39 (depends on 38)

The process of claim 38, wherein the solvent is selected from the group consisting of alkanols, benzene, toluene, trifluoro toluene, dichloromethane, dichlororethane, ethylene glycole, DMF, DMA, N-methylpyrrolidinone, acetonitrile, DMSO, and a mixture thereof.

### Claim 40 (depends on 38)

The process of claim 38, wherein the concentration of solvents is 1-50 W %.

### Claim 41 (depends on 26)

The process of claim 26, wherein the ratio of substrate/catalyst (s/C) is 5:30000.
